Related Experiment Video
Updated: Apr 30, 2026
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
1.4K
Circulating microparticles in carriers of prothrombin G20210A mutation
E Campello, L Spiezia, C M Radu
1Paolo Simioni, MD, PhD, Department of Cardiologic, Thoracic, and Vascular Sciences, Thrombosis and Haemostasis Unit, University of Padua, Via Ospedale Civile 105, 35100 Padua, Italy, Tel.: +39 049 8212667, Fax: +39 049 8212661,
Thrombosis and Haemostasis
|May 13, 2014
Summary
Prothrombin gene mutation G20210A carriers have higher levels of circulating microparticles (MP), potentially increasing thrombin generation and contributing to venous thromboembolism (VTE) risk. This highlights MP as key factors in mild genetic thrombophilia.
Area of Science:
- Hematology
- Genetics
- Thrombosis Research
Background:
- Factor V Leiden (FVL) and prothrombin gene mutation G20210A (PTM) are common genetic risk factors for venous thromboembolism (VTE).
- Previous studies indicated circulating microparticles (MP) may contribute to the thrombotic profile in FVL carriers.
- The role of MP in PTM carriers, another common genetic thrombophilia, remained less understood.
Purpose of the Study:
- To investigate the association between prothrombin gene mutation G20210A (PTM) and circulating microparticle (MP) levels.
- To determine if MP levels and activity correlate with the prothrombotic state in PTM carriers.
- To explore the potential role of MP in the development of VTE among PTM carriers.
Main Methods:
- Measured plasma levels of annexin V-MP, endothelial-MP (EMP), platelet-MP (PMP), and tissue factor-bearing MP (TF+).
- Assessed MP procoagulant activity (PPL) in 124 PTM carriers (heterozygous and homozygous) and 120 healthy controls.
- Compared MP levels and activity between PTM carriers with and without a history of VTE.
Main Results:
- PTM carriers (both heterozygous and homozygous) exhibited significantly increased levels of annexin V-MP and higher MP procoagulant activity compared to controls.
- Elevated levels of EMP, PMP, and TF+ were observed in PTM carriers versus controls.
- PTM carriers with a history of VTE showed higher MP numbers and activity, though no significant difference was found between carriers with and without VTE history.
Conclusions:
- Elevated circulating MP levels in PTM carriers may contribute to their thrombotic risk, potentially by enhancing thrombin generation.
- MP may play a role in triggering thrombotic complications associated with mild genetic thrombophilic defects.
- Further research is warranted to fully define the role of MP in the pathogenesis of VTE in PTM carriers.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K